The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson’s disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively. We assessed the Hospital Anxiety and Depression Scale (HADS-anxiety and depression subscales), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-motor (SCOPA-M)-activities of daily living (ADL) and -motor complications, Non-Motor Symptom Scale (NMSS), PDQuestionnaire-8 (PDQ-8), and levodopa-equivalent daily dose. We tested changes at follow-up with Wilcoxon signed-rank test and corrected for multiple comparisons (Bonferroni method). We identified patients with a clinically relevant anxiety improvement of anxiety based on a designated threshold of ½ standard deviation of baseline HADS-anxiety. Moreover, we investigated predictors of HADS-anxiety changes with correlations and linear regressions. We included 50 patients with clinically relevant baseline anxiety (i.e., HADS-anxiety ≥ 8) aged 63.1 years ± 8.3 with 10.4 years ± 4.5 PD duration. HADS-anxiety improved significantly at 6-month follow-up as 80% of our cohort experienced clinically relevant anxiety improvement. In predictor analyses, worse baseline SCOPA-ADL and NMSS-urinary domain were associated with greater HADS-anxiety improvements. HADS-anxiety and PDQ-8 changes correlated moderately. Worse preoperative ADL and urinary symptoms predicted favourable postoperative anxiety outcome, which in turn was directly proportionate to greater QoL improvement. This study highlights the importance of detailed anxiety assessments alongside other non-motor and motor symptoms when advising and monitoring patients undergoing STN-DBS for PD.

丘脑底核深部脑刺激 (STN-DBS) 对帕金森病 (PD) 焦虑的影响尚未得到充分研究。在本研究中，我们确定了 STN-DBS 对焦虑影响的临床预测因子。在这项前瞻性、开放标签、多中心研究中，我们评估了术前接受 STN-DBS 治疗 PD 的焦虑患者以及术后 6 个月的随访。我们评估了医院焦虑和抑郁量表（HADS-焦虑和抑郁分量表）、统一PD评定量表-运动检查、PD-运动结果量表（SCOPA-M）-日常生活活动（ADL）和-运动并发症，非运动症状量表 (NMSS)、PDQuestionnaire-8 (PDQ-8) 和左旋多巴当量每日剂量。我们使用 Wilcoxon 符号秩检验测试了后续变化，并针对多重比较进行了修正（Bonferroni 方法）。我们根据基线 HADS 焦虑的 1/2 标准差的指定阈值，确定了具有临床相关焦虑改善的患者。此外，我们还通过相关性和线性回归研究了 HADS 焦虑变化的预测因素。我们纳入了 50 名具有临床相关基线焦虑（即 HADS 焦虑≥ 8）的患者，年龄为 63.1 ± 8.3 岁，PD 持续时间为 10.4 ± 4.5 年。在 6 个月的随访中，HADS 焦虑显着改善，因为我们队列中 80% 的人经历了临床相关的焦虑改善。在预测分析中，较差的基线 SCOPA-ADL 和 NMSS-泌尿领域与较高的 HADS 焦虑改善相关。 HADS 焦虑和 PDQ-8 变化呈中等相关。术前较差的日常生活活动能力和泌尿系统症状预示着良好的术后焦虑结果，而这又与更大的生活质量改善成正比。 这项研究强调了在建议和监测接受 STN-DBS 治疗 PD 的患者时，详细的焦虑评估以及其他非运动和运动症状的重要性。